Patents by Inventor Andrew Pennell

Andrew Pennell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heteroaryl sulfonamides and CCR2
    Publication number: 20070037794
    Abstract: Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists.
    Type: Application
    Filed: July 14, 2006
    Publication date: February 15, 2007
    Inventors: Solomon Ungashe, Zheng Wei, Arindrajit Basak, Trevor Charvat, Wei Chen, Jeff Jin, Jimmie Moore, Yibin Zeng, Sreenivas Punna, Daniel Dairaghi, Derek Hansen, Andrew Pennell, John Wright
  • CCR2 inhibitors and methods of use thereof
    Publication number: 20070021466
    Abstract: Compounds are provided that act as potent antagonists of the CCR2 receptor. These compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists.
    Type: Application
    Filed: July 13, 2006
    Publication date: January 25, 2007
    Inventors: Solomon Ungashe, John Wright, Andrew Pennell, Zheng Wei, Anita Melikian
  • Azaindazole compounds and methods of use
    Publication number: 20070010524
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Application
    Filed: June 22, 2006
    Publication date: January 11, 2007
    Applicant: ChemoCentryx, Inc.
    Inventors: Penglie Zhang, Andrew Pennell, John J. Wright, Wei Chen, Manmohan Leleti, Yandong Li, Lianfa Li, Yuan Xu
  • Azaindazole compounds and methods of use
    Publication number: 20070010523
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Application
    Filed: June 22, 2006
    Publication date: January 11, 2007
    Applicant: ChemoCentryx, Inc.
    Inventors: Penglie Zhang, Andrew Pennell, John J. Wright, Wei Chen, Manmohan Leleti, Matthew Ronsheim
  • Heteroaryl sulfonamides and CCR2
    Publication number: 20060173019
    Abstract: Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists.
    Type: Application
    Filed: January 13, 2006
    Publication date: August 3, 2006
    Inventors: Solomon Ungashe, Zheng Wei, Arindrajit Basak, Trevor Charvat, Jeff Jin, Jimmie Moore, Yibin Zang, Sreenivas Punna, Daniel Dairaghi, Derek Hansen, Andrew Pennell, John Wright
  • Aryl sulfonamides
    Publication number: 20060111351
    Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
    Type: Application
    Filed: October 20, 2005
    Publication date: May 25, 2006
    Inventors: Solomon Ungashe, John Wright, Andrew Pennell, Zheng Wei, Anita Melikian
  • Substituted piperazines
    Publication number: 20060106218
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Application
    Filed: December 8, 2004
    Publication date: May 18, 2006
    Applicant: ChemoCentryx, Inc.
    Inventors: Andrew Pennell, James Aggen, J.J. Wright, Subhabrata Sen, Brian McMaster, Daniel Dairaghi, Wei Chen, Penglie Zhang
  • Bicyclic and bridged nitrogen heterocycles
    Publication number: 20060074121
    Abstract: Compounds are provided that act as potent modulators of one or more of the CCR1, CCR2 and CCR3 receptors. The compounds are generally fused-, spiro- or bridged-nitrogen heterocycles having an aryl and heteroaryl component and are useful in pharmaceutical compositions, methods for the treatment of CCR1-, CCR2- and/or CCR3-mediated diseases, and as controls in assays for the identification of competitive receptor antagonists for the above chemokine receptors.
    Type: Application
    Filed: September 1, 2005
    Publication date: April 6, 2006
    Applicant: ChemoCentryx, Inc.
    Inventors: Wei Chen, Penglie Zhang, James Aggen, Daniel Dairaghi, Andrew Pennell, Subhabrata Sen, J.J. Wright
  • Substituted piperazines
    Publication number: 20050256130
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Application
    Filed: November 1, 2004
    Publication date: November 17, 2005
    Applicant: ChemoCentryx, Inc.
    Inventors: Andrew Pennell, James Aggen, J.J. Wright, Subhabrata Sen, Brian McMaster, Daniel Dairaghi, Wei Chen, Penglie Zhang
  • Bicyclic and bridged nitrogen heterocycles
    Publication number: 20050234034
    Abstract: Compounds are provided that act as potent modulators of one or more of the CCR1, CCR2 and CCR3 receptors. The compounds are generally fused-, spiro- or bridged-nitrogen heterocycles having an aryl and heteroaryl component and are useful in pharmaceutical compositions, methods for the treatment of CCR1-, CCR2- and/or CCR3-mediated diseases, and as controls in assays for the identification of competitive receptor antagonists for the above chemokine receptors.
    Type: Application
    Filed: March 2, 2005
    Publication date: October 20, 2005
    Applicant: ChemoCentryx, Inc.
    Inventors: Andrew Pennell, James Aggen, J.J. Wright, Subhabrata Sen, Wei Chen, Daniel Dairaghi, Penglie Zhang
  • Aryl sulfonamides
    Patent number: 6939885
    Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
    Type: Grant
    Filed: November 17, 2003
    Date of Patent: September 6, 2005
    Assignee: Chemocentryx
    Inventors: Solomon Ungashe, Zheng Wei, John Jessen Wright, Andrew Pennell
  • Aryl sulfonamides
    Publication number: 20050165067
    Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
    Type: Application
    Filed: January 27, 2005
    Publication date: July 28, 2005
    Inventors: Solomon Ungashe, Zheng Wei, J.J. Wright, Andrew Pennell
  • Aryl sulfonamides
    Publication number: 20050137193
    Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
    Type: Application
    Filed: May 13, 2004
    Publication date: June 23, 2005
    Inventors: Solomon Ungashe, J. Wright, Andrew Pennell, Zheng Wei, Anita Melikan
  • Bis-aryl sulfonamides
    Publication number: 20050137179
    Abstract: Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.
    Type: Application
    Filed: May 19, 2004
    Publication date: June 23, 2005
    Inventors: Solomon Ungashe, Zheng Wei, J. J. Wright, Andrew Pennell, Brett Premack, Thomas Schall
  • Aryl sulfonamides
    Publication number: 20040171654
    Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
    Type: Application
    Filed: November 17, 2003
    Publication date: September 2, 2004
    Inventors: Solomon Ugashe, Zheng Wei, J. J. Wright, Andrew Pennell
  • Bis-aryl sulfonamides
    Publication number: 20040167113
    Abstract: Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.
    Type: Application
    Filed: November 18, 2003
    Publication date: August 26, 2004
    Inventors: Solomon Ugashe, Zheng Wei, J.J. Wright, Andrew Pennell, Brett Premack, Thomas Schall